The BDC 2.5 T cell clone is specific for pancreatic ]3-cell antigen presented by I_Ag7, and greatly accelerates diabetes when injected into 10-21-d-old nonobese diabetic (NOD) mice. The BDC 2.5 T cell receptor (TCI<) has been solubilized as a TCR.-IgG1 chimeric protein.
A s a result of the somatic recombination of TCR gene segments in developing T cells, each TCIL contains some structural epitopes that are unique to a particular T cell clone and some that are shared among different clones (1) . Immunity against a TCR could therefore regulate the function of either a specific T cell clone or a set of clones in vivo, depending on the nature of the epitope recognized. In the rat and mouse models of experimental autoimmune encephalomyelitis (EAE) l, oligoclonal suppression of autoreactive T cells appeared to occur after immunization with peptides derived from the ix-or [3-chains of the TCIL of encephalitogenic T cells. Immunization of Lewis rats with synthetic peptides based on the V13-8.2 CDtL2 (2) or V~-D[3-JI3 (3) sequences of the TCP,. of rat encephalitogemc T cells suppressed the induction of EAE. immunization of B10.PL or (SJL × B10.PL) F i mice with a pepude derived from framework region 3 of the TCFL V[3-8.2 chain protected both strains against EAE (4, 5) . Similar immunizations of DBA/2 or (PLJ × SJL) F 1 mice with a V[3-8.2 CDR2 peptide appeared to induce clonal anergy in all V[3-8.2 + T cells (6) . The mechanism of regulation by TCIL 1Abbreviations used m thts paper, dc, dual chain; EAE, experimental autoammune encephalomyelitis; HRP, horseradish peroxtdase; MOI, multlphcity of refection; NOD, nonobese diabetic; sc, single chain; SS-, cell surface staining negative; SS +, cell surface staining poslnve.
peptide immumzation is thought to involve primed CD4 + (5) or CD8 + (6) T cells that recognize the peptide in association with MHC molecules on the surface of either an APC or the autoreactive T cell itself (7) . Although there are experimental data suggesting that T cells primed against the TCR V[3-8.2 CDR2 peptide can inhibit the activation of myelin basic protein--specific encephalitogenic rat T cells in vitro (8) , the details and immunosuppressive effects of the mechanism are uncertain. T cells have yet to be shown to process their own TC1L and present MHC-associated epitopes. Likewise, it is not known whether professional APC present TCR epitopes derived from autoimmune T cells in the course of disease. Furthermore, in rat EAE, immunizatlon with the V~-8.2 CDIL2 peptide sometimes increased the seventy of disease and converted the normally acute, self-limiting disease into a chronic disorder (9) .
An alternative approach to immunotherapy is to perform TCIt. immunizations designed to induce antibodies against TCI< variable region epitopes expressed on the T cell surface. The ability of injections of V[3-8.1/.2 family-specific mAb to prevent EAE in mice (10) suggests the feasibility of this approach. Although it has been shown that immunization with peptides representing TCI< V[3-8.2 CDR2 (11), conserved VDJ, and consensus JR sequences (3) could stimulate the production of antibodies recognizing cell-surface TCtL, V[3-8.2 CDR2 peptide immunization was not always successful in stimulating such a response in rats (9) .
Moreover, several peptides based on the sequence of mouse TCP,. V13-6 stimulated antibody responses against the peptides but not the intact TCR (12) . To investigate immunoregulation resulting from an antibody response against TC1L epitopes, a more reliable immunogen is required. Fortunately, newly developed techniques for the production of soluble TCR (13--16) now allow immunization with proteins containing the extracellular domains of the TCR. Such immunization should stxmulate the immune system with an array of different T cell epitopes, some of which are likely to resemble those of native cell-surface TCR.
The BDC 2.5 T cell clone is l-AgV-restricted and specific for pancreatic islet [3-cell antigen (17, 18) . In vivo, it accelerates the onset of &abetes when injected into young nonobese diabetic (NOD) mice (19) . We have produced soluble recombinant BDC 2.5 TCR by constructing a chimeric protein composed of the extracellular domains of the TCR chains (Vot-1/Cot, and V [3-4/C[3) linked to the hinge, CH2 and CH3 domains of the mouse IgG1 heavy chain. The technique is similar to that used for the production of a y/8 TCR in transiently transfected COS cells (20) ; but we have used a baculovirus expression system shown previously to allow the successful production of soluble 0t/j3 TCP, from the D0-11.10 T cell hybridoma (21) , and the N15 cytotoxic T lymphocyte clone (22) .
The studies reported here characterize the immunological specificity of the antibody response to BDC 2.5 TCP,.-IgG1 protein in NOD mice. Unlike rat and mouse EAE, diabetes in the NOD mouse does not involve obviously restricted TCR Voe or V[3 gene segment usage (23) , and it is extremely unlikely that immunization with a single TCP,. would affect the natural progression of disease. We have therefore investigated the ability of antibodies raised against BDC 2.5 TCR-IgG1 to protect against the adoptive transfer of diabetes by the BDC 2.5 T cell clone in young'NOD mice. Because the recipient NOD mice are injected with BDC 2.5 cells between 10 and 21 d of age, they are too immature to be actively immunized. We have overcome this difficulty by immunizing female NOD mice and mating them. Their offspring have been investigated for the effect of maternally transferred anti-TCR antibodies on the diabetogenic activity of injected BDC 9.2.5 T cells.
Materials and Methods
Mice. NOD mice were purchased from Taconic Farms (Germantown, NY), NOD/LtRIP-Tag transgenic mice (24) from the Ammal Resources Unit of The Jackson Laboratory (Bar Harbor, ME), and AKR/J mice from The Jackson Laboratory. The RIPTag transgene is a recombinant simian virus 40 oncogene in whmh the rat insulin 5' promoter has been inserted immediately upstream of the simian virus 40 early region (25) , Transgene expression is restricted to the [B-cell and results in the formation of [B-cell tumors in the pancreas in vivo. Offspring of crosses between NOD/Lt RIP-Tag and normal NOD mice were weaned and prowded with 5% (wt/vol) sucrose-supplemented water, and sugar cubes. From 10 wk of age, blood glucose levels were closely momtored, and when the mice became severely hypoglycemic (blood glucose concentration --<50 mg/dl) they were killed for islet cell preparation.
T Cell Lines. The pancreatic [3-cell-specific, l-AgT-restricted, NOD mouse T cell clones, BDC 2.5 and 6.9, were propagated as previously described (17, 18) with the mochfication that x-irradiated (5,000 rids) Met cells isolated from NOD/LtlKIP-Tag mice were substituted for conventional NOD mouse Mets as a source of antigen. Before antigen-specific prohferanon assays, BDC 2.5 and BDC 6.9 cells were rested for at least 14 d after the last stimulation with antigen and spleen cells. The T cell responses were assayed in U-bottomed 96-well plate cultures. Each well contamed 2 X 104 cloned T cell and 5 X 10 s x-irradiated (3,000 rads) NOD spleen cells as a source of APC in 200 ~1 Eagle's Hank's atmno acid medium (Irvine Scmntific, Santa Ana, CA) supplemented with 5% FCS (Hyclone Laboratones, Logan, UT), 2 mM glutamme, 100 U/ml penicillin, 100 U/ml streptomycin, and 5 X 10 -s M 2-ME. Cultures were set up with and without 7.5 X 103 x-irra&ated (5,000 rids) Met cells as a source of ant> gen, incubated at 37°C m 5% CO2 for 96 h, and pulsed with 1 IxCi [3H]thymidme (6.7 C1/mmol; ICN, Irvlne, CA) for the final 16 h of incubation. The cultures were harvested, and isotope incorporation measured by scintillation counting. The mean counts per minute were calculated from triphcate cultures.
The lsolation and in vitro propagation of the I-At-restricted, hen egg conalbumm peptide-speclfiC AKIL mouse T cell clone, D10 (TCIL Vo~-2/V[3-8.2), has been descnbed previously (26) . The B1 T cell line was derived from the spleen of an ummmunlzed NOD mouse. The B1 cells appear to be specific for an unidentified autoantlgen of NOD spleen cells. Although no cloning procedure was used, 100% of the cells express TC1K V[~-8.1/2 as determined by m~munofluorescent stainmg. The B1 line was propagated in vitro similarly to the D10 line, except that x-Irradiated NOD spleen cells were used as a source of antigen. The I-E kresmcted, pigeon cytochrome C peptide-specific mouse T cell clone, B10 (TC1K Va-11/V[3-16), was kindly provided by Dr. S.M. Hedrick (Department of Biology, Umversity of California, San Diego); it was propagated m vitro as described previously (27) .
Cloning of TCR and IgG1 Genes. Total RNA was prepared from ~5 X 10 ~ cells (28) and 1.0 }xg converted to single-stranded cDNA using superscript reverse transcriptase (GIBCO/BRL, GaIthersburg, MD) according to the manufacturer's protocol. TCR and [gG1 genes were amplified from 5% of each cDNA preparation in 75-txl reactions containing: 10 mM Tns-HC1, pH 8.3, 50 mM KC1, 0.001% (wt/vol) gelatin, 1.5 n'~Vl MgCI2, 200 mM dNTPs, 2.5 U AmpliTaq DNA polymerase (Perkin Elmer Corp., Branchburg, NJ), and 270 nM of each primer. Primers were designed using published gene sequences encoding the TCR V[3-4, Vow-l, CoL and CI3 segments, and the IgG1 heavy chain constant-regmn (23, 29, 30) . The primer pairs for the BDC 2.5 TCR [B-chain cDNA were: MusVi3-4, 5'-CCTCTAGAAGAT-CTCCATGGGCTCCATTTTCCTCAGTT-3'; and 5'D1013, 5'-GGAATTCAGATCTCCGTCTAGTCGTGATGAACCA-CGAGGTACCAGATCAG-3'. The primer pa,rs for the BDC 2.5 or-chain cDNA were: MusV0t-1, 5'CCTCTAGAAGAT-CTGCATGCATTCCTTACATGTTTCACTA-3 '; and 5 'D 100t, 5'-GGAATTCAGATCTGATGGAGCAGTCGTTGATCCA-CGTGGTACCAGGTC-3' The primer pairs for the IgG1 hinge, CH2 and CH3 cDNA were: 5'-IgG1, 5'-GCTGGTACCCAGGGGTAGTGGTTGTAAGCcTTGcATATGTAcAGT-CCCAGAAGA-3'; and 3'-IgGl, 5'GAAGATCTcATTTACCA-GGAGAGTGGGAGAGGCTCTTCTC-3'
Cycling parameters were 95°C for 30s, 62°C for 30s, and 72°C for 60s for 30 cycles. PCtK products were ctoned into the vector pC1KII (Invitrogen, San Daego, CA) to yield the plasmids pCIL-BDC25o~, pC1L-BDC2513, and pC1L-IgG1. The cloned genes were completely sequenced using Sequenase (United States Biochermcals, Cleveland, OH) and the manufacturer's protocol. They were found to be adentical to published sequences (23, 31) .
Construction of Baculovirus Transfer Vectors. Standard techniques were used for construction of recombinant DNA (32) . p5/598 and p7/598 (Fig. 1 B) were constructed by hgating into either the BamHI or BglII sites of the polyhedrin/Pl0 'double-promoter' plasmid, pAcUW51 (Pharmingen, San Diego, CA), both a BglIIKpnI, BDC 2.5 TCtL [3-chain cDNA fragment from pCR-BDC2513, and a KpnI-BglII, IgGl cDNA fragment from pC1L-IgG1. Next, the BDC 2.5 TCR-IgG1 baculovirus transfer-vector p20/599 (Fag. 1 B) was made by hgating between the EcoRI and KpnI sites of p5/598 an EcolLI-BamHI fragment encoding the BDC 2.5 TCR [3/IgG1 chimeric chain from p7/598, and two fragments from pCP,-BDC25ci; a BgllI-PvulI fragment and a PvulI-KpnI fragment, which together encode the BDC 2.5 TCR or-chain.
Two "single-promoter" recombinant transfer vectors with genes encoding BDC 2.5 TCP, sangle or-and [3-chains as IgG1 chimeras downstream of the polyhedrln promoter were also constructed, p7/599 was constructed by hgating into the BamHI site of pVL941 both a BgllI-KpnI BDC 2.5 TClL c~-chain cDNA fragment from pCR-BDC25c~, and the Kpnl-BgllI IgG1 fragment for pCR-IgG1. Similarly, p3/598 was constructed by hgating into the BamH1 sate ofpVL941(PharMingen) both the BgllIKpnI, BDC 2. To produce TCR-IgG1 protein for purificataon, Sf9 or High 5 (Invitrogen) cells were grown at 27°C in 6-8 1 spinner cultures an serum-free SF900II medium (GIBCO/BRL) supplemented with 10 U/ml penicallln, 100 ~zg/ml streptomycin, and 0.25 ~g/ ml amphotericin B (Sigma Chemical Co., St. Louis, MO). When the cell concentration reached 0.8-1.2 × 106/ml the cultures were infected with recombinant baculovirus at a multiplicity of infection (MOI) of 5 and incubated for a further 3 d. Supernatants were harvested by centnfugation and filtration through a I).2-~m filter.
To compare the expression levels of soluble TCR during refection wath different recombinant baculovlrnses, small-scale infecnons were performed. Duplicate or triplicate 60-mm &shes were seeded wath 2 × 106 Sf9 cells an trichoplusla hi medium Fred Hank medium (JRH Sciences, Lenexa, KS). After the cells had attached (15-60 min) they were infected at a MOI of 5 with recombinant baculovirns. After 3 d the culture supernatants were harvested.
Recombinant Proteins. The producnon of D10 scTCR in Es&erichia coli will be described elsewhere (Khandekar, S.S., P.P. The hybndoma producing the TCR C[3-specific mAb, 501.1.1, was derived from the spleen of a NOD mouse that had been primed and boosted with soluble BDC 2.5 TC1L-IgG1 as described below. 4 d after the final l.p. injecnon of antigen, the spleen cells were fused with P3X63-Ag8.653 myeloma cells (American Type Culture Collection, Rockville, MD) using standard procedures (36) .
The D10 T cell clone-specific mAb 3D3 (26) was purified by protein A affimty chromatography.
Immunoqffinity Chromatography. 30 mg of mAb H57 were covalently coupled to 15 ml of protein A beads (Rephgen, Cambridge, MA) using dimethylplmehmidate as described (37) . Baculovirus-infected insect cell supernatants were concentrated approximately fivefold using a concentrator with a 10-kD membrane filter (Pellicon; Millipore, Bedford, MA), filtered through a 0.2-~m filter, and passed over a H57-protem A column at 4°C wath a flow rate of 1-2 ml/rnln. The column was washed with 10 column-volumes of PBS and eluted wath 50 mM catrate, pH 3.0. Eluted fractions were neutralized with 1 M Tris-HC1, pH 8.8, and dialyzed against PBS. Protein concentrations were determined by the Bradford method (38), using BSA as a standard.
Using samilar procedures, mAb 3D3-proteln A columns were prepared and used to purify the soluble D10 TCR preparations: D10 dcTCR, D10 scTCR, and D10 TCR-IgG1 (Khandekar et al., manuscript submitted for publicanon), mAb H28 and H57 columns were used to purify soluble D10 TCR ci-and [3-chain protems.
hnmunoprecipitations, SDS-PAGE Analysis, and Immunoblotting. BDC 2.5 TCR-IgG1 was precipatated by standard procedures (39) using an overnight 4°C incubanon with 10 ~tl anti-CoL H28 or anta-C[3 H57 mAb covalently coupled protean A beads. 4 × 107-6 × 107 T cells were lysed in TBS contalmng 0.2% NP-40 (Sigma Chemical Co.) and protease inhabitors (1 mM PMSF, NoL-p-tosyl-c-lysine chloromethyl ketone, EGTA, and EDTA; 2 ~zM leupeptln and pepstatin; 0.6 TIU/ml aprotanan; Sigma) at 107 cells/ml for 45 min on ice. Lysates were clarified by centrifugation and each lysate was incubated wath 100 txl of H57 mAbcoupled protean A beads for 4 h. Subsequent steps in the analyses of both BDC 2.5 TCR-IgG1 and T cell-derived TCR were similar. The beads were extensively washed with TBS containing either 0.5% Triton X-100 for recombinant TCR or 0.05% NP-40 for T cell-derived material, and the TCR proteins eluted by boiling an SDS sample buffer (2.3% SDS, 10% glycerol, 62.5 mM Tris-HC1, pH 6.8) for 3 man, with or without 5% 2-ME. The eluted proteins were fractionated by 10.5% or 12.5% SDS-PAGE (40) . Protein bands were stained with Coomassie brilliant blue. For Western blotting, proteins were separated by nonreducing SDS-PAGE, transferred directly to Immobllon-P membrane (Milhpore), and probed with antisera or mAbs diluted in PBS. Annbody reactivity was detected with either polyspeclfiC goat ann-mouse Ig antibody conjugated to horseradish peroxidase (HRP) (Cappel Laboratories, Durham, NC) or goat anti-hamster IgG-HRP (Cappel) at a 1:2,000 dilution. Western blots were visualized using the enhanced chemiluminescence technique (ECL; Amersham Corp., Arlington Heights, IL). In some experiments the membranes were stripped and reprobed according to the manufacturer's recommendations.
Analysis of BDC 2.5 TCR-IgG1 by BIAcore.
The binding of TC1K Ca-specific H28 mAb and C~-speclfiC H57 mAb to BDC 2.5 TCR-IgG1 protein was analyzed using the BIAcore biosensor (Pharmacia LKB Blotechnology Inc., Plscataway, NJ). 0.6 Ixg of immunoaffinity-punfied BDC2.5 TCR-IgG1 was coupled to dextran surface by standard amine chennstry (41) . A blank control surface was activated and blocked in the absence of soluble TCR. Affinity-purified H57 and H28 mAb (each at 3 IxM) were injected over a control surface or over the BDC 2.5 TCR-IgG1-coupled surface. The mAb were dialyzed against and diluted in Hepes-buffered saline (10 mM Hepes, 150 mM NaC1, 3.4 mM EDTA, 0.005% surfactant P20, pH 7.4). Samples of 20 IM were injected at a flow rate of 5 IM/min and this flow rate was maintamed throughout the experiment. Where necessary, the bmsensor surface was regenerated with 10 mM HC1. All binding experiments were conducted at 25°C. The surface plasmon resonance signal was recorded as resonance units versus time and the data plotted as a "sensorgram."
Immunofluorescence Staining and Flow Cytometry. ELISA. The amounts of soluble heterodimeric BDC 2.5 TCR-IgG1 produced in the baculovlrus expression system were estimated by a direct sandwich ELISA. 96-well plates (MaxiSorp; Nunc, Naperville, IL) were coated overnight with 4 btg/ml TCR C[3-specific H57 mAb at 4°C, and blocked with 1% BSA in borate-buffered saline for 2 h at room temperature. 100-pA samples of soluble TCR diluted in borate-buffered saline with 1% BSA were added overnight at 4°C. The plates were then washed and biotin-conJugated TCR Cot-specific H28 rnAb (1:500 dilunon) was added to each well. After 4 h incubation at room temperature the plates were washed and developed with phosphatase-labeled streptavidin (Kirkegaard and Perry Labs, Gaithersburg, MD) and 104 substrate (Sigma Chemical Co.). The OD at 405 nm was measured and the amounts of soluble heterodimeric BDC 2.5 TCR-IgG1 were estimated by comparison of OD values with a standard curve obtained with a reference preparation of H57 mAb affimty-purlfied BDC TCR-IgG1 protein.
For the analysis of serum antibodies from mice immunized with soluble recombinant TCR, 96-well plates were incubated overnight at 4°C with soluble TCR preparations at a concentration of 4 ~zg/ml in borate-saline buffer, pH 8.5. Plates were washed and blocked by standard procedures (42) . The solid phase was incubated overnight at 4°C with NOD nonimmune serum or antiserum, or TCR-speclfic mAb, followed by an incubation with alkaline phosphatase-conjugated antibodies specific for mouse Ig K-and h-hght chains. When TCR ot-cham, V13-8, and Votspecifc biotlnylated mAb were used in the first step, alkahne phosphatase conjugated streptavidin was used instead of the antilight chain antibodies. The binding of antibodies was measured as absorbance at 405 nm after reaction of the immune complexes with 104 phosphatase substrate (Sigma Chemical Co.).
Immunizations. NOD Pancreatic Islet Isolation, and T Cell Purification. Islet cells were isolated from (NOD/Lt RIP-Tag X NOD) F 1 mouse pancreata as previously described (43), but with the modification that immediately after death the pancreas was infused with a collagenase (Boehringer Mannhmm) solution (4.0 mg/ml) via the common bile duct. The pancreas was excised, incubated in vitro for 15 mm at 37°C, and the encapsulated tumors dissected from exocrlne tissue and forced through a 70-~m nylon mesh (cell strainer; Falcon, Oxnard, CA) to produce a single cell suspension.
Normal mouse T cells were purified from spleen cells using T cell enrichment columns (R & D Systems, Minneapolis, MN) according to the manufacturer's instrucnons.
Adoptive Transfer of Diabetes by BDC 2.5 and BDC 6.9 T Cell
Clones. The procedure was essentially that described previously (19) . NOD mice between 10 and 21 d of age were injected with 5 × 106 to 10 × 10 ~'T cells inavolume of 0.5 ml. A total of three rejections spaced at weekly mtervals was administered. Urinary sugar was momtored using test tape (Eli Lilly and Co., Indianapolis, IN) and the onset of diabetes was confirmed by measuring blood sugar levels with a Glucose Analyzer 2 (Beckman Instruments Inc., Palo Alto, CA). A blood sugar concentration of >10 mM indicated diabetes. Experiments were termmated as soon as diabetes was diagnosed or by 4 wk after the first injecnon ofT cells.
Results

Characterization of Soluble TCR-IgG1 Chimeric Receptors.
A schematic diagram of the TCR-IgG1 chimeric protein encoded by the recombinant baculovlrus is shown in Fig.  1 A. TCR derived from the NOD mouse BDC 2.5 (TCR VcI-1/V[3-4) T cell clone (18, 23) was expressed as a soluble TCR-IgG1 chimeric protein. Supematants from Sf9 or High 5 cells infected with v20/599 (BDC 2.5 TCR-IgG1) recombinant baculovirus were fractionated by immunoaffinity chromatography on a TCP,-C[3~specific, H57 mAb column. The bound and eluted BDC 2.5 receptor protein was analyzed by SDS-PAGE (Fig. 2 A) ing conditions, the purified receptor migrated as a major species of 110 kD, with a smaller amount of material at ~200 kD. After reduction, the protein showed a band at 50-55 kD, indicating that both nonreduced species were formed by the disulfide linkage of50-55-kD subunits. The predicted molecular masses of the BDC 2.5 TCR ot-chainIgG1 and ~-chain-IgG1 polypeptides are 50,355 D and 55,319 D. The apparent molecular masses of 50--55 kD for the polypeptides are consistent with these values. Some variation in molecular mass of the recombinant protein is to be expected due to the variable high mannose-type N-hnked glycosylation which is known to modify recombinant proteins synthesized in baculovirus-infected insect cells (44) (45) (46) . The data are also consistent with the major nonreduced 110-kD species being a dimer of a 50-55-kD subunit. The minor amounts of nonreduced species of higher molecular mass presumably represent oligomers formed by atypical disulfide bond formation. The pre'sence of TCR ot-and ~-chains in the immunoamnity purified TCP,. A direct s a n d w i c h ELISA similar to that described by C h a n g a n d colleagues (22) .,,,.,,,., (6) buffer alone (line), ( (Fig. 4) , whereas the supernatants of cultures simultaneously infected with both v7/599 and v3/ 598 contained heterodimeric material at a level of 500 ng/ ml when the ratios of the v7/599:v3!598 MOI were 10:10 and 10:5. The ELISA could therefore be used with confidence to routinely monitor the amounts of heterodimeric BDC 2.5 TCR-IgG1 protein purified from the supernatants of large scale Sf9 and High 5 spinner cultures infected with the "double-promoter" recombinant baculovirus v20/599 encoding both the chimeric TCP,. cx-IgG1 and [3-IgG1 constructs. In five batches, varying in volume from 3 to 7 liters, 0.5-1 mg/liter was routinely obtained after H57-lmmunoaffinity purification. This represented an overall yield of 12.5-25% since the unfractionated culture supernarants appeared to contain °°4 mg/liter as estimated by the ELISA.
Tile Antibody Response to the BDC 2.5 TCR-IgG1 Chimeric Protein. NOD mice were primed with the BDC 2.5 TCP,:IgG1 protein in CFA. Boosting injections without adjuvant were given 14-21 d after priming and repeated aSer a further 14 d. All antisera collected 4 d after the second boosting were found to contain antibodies recognizing the soluble BDC 2.5 TCR-IgG1 protein by the ELISA, whereas indirect immunofluorescence revealed that 18 out of the 32 animals immunized made antibodies that bound the surface of the BDC 2.5 T cell clone (TCR: Ve~-I/V [3] [4] . Each of these 18 antisera appeared to be specific for the BDC 2.5 clone because BDC 6.9 cells (TCR.: V~x-13.1/VI3-4) were not stained. The antisera reacting only in the ELISA were pooled, and the pool will be referred to as cell surfacestaining negative (SS-). The 18 antisera that both reacted in the ELISA and stained the BDC 2.5 cells were also pooled to produce a cell surface-staining positive pool (SS+).
Analysis of the SS + pool indicated that the antibodies produced in response to BDC 2.5 TCI:L-IgG1 immunization and which recognized the BDC 2.5 cell surface were clonotype specific. The data are shown in Fig. 5 A. The antiserum pool stained BDC 2.5 T cells but not BDC 6.9 T cells or normal splenic NOD T cells, suggesting that the antibodies recognized clonotypic epitopes of the BDC 2.5 TCR. Detailed mapping of these epitopes in the variable region of the BDC 2.5 TCP,. was not possible due to the lack of mAb specific for this receptor; however, some association with the V~-4 segment was indicated by the initial observation that individual mouse antisera could inhibit the binding of V[3-4 family-specific, FITC-labeled mAb to the BDC 2.5 cell surface. Data obtained with the SS + pool are shown in Fig. 5 B. BDC 2.5 cells were incubated with antiserum, nonimmunized NOD mouse serum, or buffer, washed, and stained with anti-VI3-4 or anti-C~ FITCmAb. Pretreatment with the anti-BDC 2.5 TCR-IgG1 antiserum reproducibly inhibited staining with the anti-V[3-4 mAb in comparison with pretreatment with nonimmune serum. As expected, given the apparent clonotype specificity of the antiserum (Fig. 5 A) , it did not interfere with the binding of the Cl3-specific, H57 n-LAb any more strongly than nommmune serum.
Antibodies recognizing TCI< clonotypic epitopes are usually able to inhibit the antigen-specific responses of the appropriate T cell clone in vitro (47) . Likewise, the SS + antiserum strongly inhibited the in vitro proliferative response of the BDC 2.5 cells to antigen, but had no effect on the response of the BDC 6.9 cell (Fig. 6 ). The responses of both the BDC 2.5 and BDC 6.9 T cell clones were stimulated by irradiated NOD mouse spleen cells as a source of APC, and NOD/LtRIP-Tag pancreatic islet cells as a source of antigen.
The TCR specificities of the SS-and SS + pools were compared by ELISA using different soluble TCR immobihzed on the plates. Both SS-and SS + antlsera bound to BDC 2.5 TCR-IgG1 and D10 TCR-IgG1 (TCR Vow-2/ V[3-8.2) proteins ( Fig. 7 A) ; the latter receptor was derived from the hen egg conalbumin-specific and I-Ak-restricted D10 T cell clone (26) . The cross-reaction appeared to be due to antibodies specific for epitopes of the o~-and [3-chains of the TCR rather than the IgG1 constant region domains of the chimeric protein because the antisera recognized the D10 dcTCR, and the D10 TCR individual cx-and ]3-chains (Fig. 7 A) . These D10 TCR proteins were produced in soluble form by deletion of the transmembrane and cytoplasmic portions of the TCR without the addition of the CH2 and CH3 domains oflgG1. In each, the carboxyl terminus was formed by the amino acid immediately following the cysteine residue that participates in interchain disulfide bond formation. Both the SS + and SS-antisera failed to recognize the D10 single-chain (sc) TCR containing only the Vot and V[3 segments joined by a synthetic linker of 27 amino acids (Fig. 7 A) . That the variable region of the DI0 scTCR was intact was demonstrated by the ELISA data showing the presence of the conformational, clonotypic epitope recognized by the 3D3 mAb (Fig. 7 A) . Both the V[3-8 and Vow-2 family-specific epitopes were also present (data not shown). The absence of reactivity of the SS + and SS-antisera with the D10 scTCR therefore suggests that the cross-reactivity with the D10 dcTCR, and the o~-chain and [3-chain proteins was due to antibodies specific for the TCR Cc~ and C[3 domains.
The question arose as to why the SS + antiserum was apparently specific for TCR clonotypic epitopes detected by indirect immunofluorescent staining of the BDC 2.5 cell surface and yet broadly cross-reactive against different soluble TCR by the ELISA. There were two possible explanations. Either the constant region epitopes recognized in the soluble TCR were unavailable for antibody binding in the cell membrane-bound native BDC 2.5 TCR, or the soluble TCR expressed unique Col and C13 deterrmnants formed by posttranslational modification, e.g., glycosylation, specific to the baculovirus-infected insect cell. To address these possibilities, TCR were immunoprecipitated by the anti-C[3 mAb, H57, from NP-40 detergent extracts of BDC 2.5 (TCR Vow-l/V[3-4), BDC 6.9 (TCR Vot-13.l/ V[3-4), B10 (TCR Vo~-11/V [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , and D10 (TCR VoL-2/ V[3-8.2) T cell clones, and analyzed by 10.5% SDS-PAGE under nonreducing conditions. Immunoblots were then performed with the same SS + and SS-antiserum pools previously analyzed by the ELISA. The reactivity of both antisera with material of ~90 kD (Fig. 7 B) , regardless of the T cell source, indicated the presence of antibodies specific for linear, constant region epitopes of the T cell-synthesized TCR. Control mAb recognizing constant regions of TCR or-(H28) and [3-(501-1.1) chains reacted with material of identical size for each TCR. In addition, both the SS + and SS-antisera have been shown to immunoprecipitate TCR released by NP-40 detergent extraction of the BDC 2.5, BDC 6.9, D10 and B10 T cell clones (data not shown), indicating that denaturation of the TCR in SDS is not required for exposure of the constant region epitopes recognized by the antisera.
Maternal Immunization with BDC 2.5 TCR-IgG1 Protects Young NOD Offspring from Diabetes Induced by the Adoptive
Transfer of the BDC 2.5 T Cell Clone. One group of 8-10-wk-old female NOD mice was immunized with BDC 2.5 TCR-IgG1 protein. A second group was similarly immunized with the D10 TCR-IgG1 protein, and a third group was not immunized. All the mice were mated with 8-10-wk-old male NOD mice. In the immunized groups, mating began on the day of the first boosting injection, and pregnant mice were further boosted by the intravenous injection of 20 p,g TCR-IgG1 between days 13 and 16 of ~x-chain, and D10 scTCP., After incubation with the sera or anUbodies indicated on the ordinate, antibody binding to the plated TCR was detected by alkaline phosphatase-coupled antibodies specific for mouse Ig K and k light chains. TCR ~x-chaln (H28)-and [3-chain (H57) -specific mAb, and the 3D3 mAb were blotxnylated, and their bindIng was detected with alkahne phosphatase-coupled streptavadm. The ELISA show that NOD mouse antl-BDC 2.5 TCR-IgG1 SS-and SS + antasera reacted with epatopes shared by BDC 2.5 TCR-IgG1, D10 TCR-IgG1, D10 dcTCR and the D10 TCR 0~-and [3-chains, but not with DI0 scTCR that lacked the TCR constant-regaons. (/3) Equivalent numbers of cells from each of the four T cell clones (BDC 6.9, B10, BDC 2 5, and D10) were lysed In NP-40, and the TCR were lmmunoprecipatated with anta-TCR CIJ-speclfiC mAb H57 as described In Materials and Methods. Protein was separated by SDS-PAGE under nonreduclng conditions and lmmunoblotted with the indicated serum (1:200 ddution). H28 mAb was used at 4 ~g/ml, and 501 1.1 mAb was used as a hybndoma supernatant Antibody reactivity was detected with either polyspeclfiC goat anti-mouse Ig Ab conjugated to HILP or goat anti-hamster IgG-HlkP at a 1:2,000 dilution as descrabed In Matenals and Methods. gestation. N u r s i n g m o t h e r s w e r e given final boosts 14 d later. Sera w e r e collected 4 d after the final boost, a n d i n d irect i m m u n o f l u o r e s c e n t cell surface staining (described earlier in Results) was used to d e t e r m i n e w h i c h B D C 2. T h e onset o f diabetes was m o n i t o r e d , and the data are p r e s e n t e d in Table 1 . As e x p e c t e d f r o m p r e v i - ously published data (19) , both BDC 2.5 and BDC 6.9 T cells induced the early onset of diabetes. Disease occurred between 10 and 25 d after the first injection of cells in 30-50% of pups delivered by nonimmunized mothers, as opposed to the natural time of onset, which is usually at >3 mo of age in unmanipulated NOD mice. Immunizations of mothers that successfully resulted in a BDC 2.5 TCR. clonotypespecific antibody response appeared to completely protect their pups from the induction of diabetes by the adoptive transfer of the BDC 2.5 T cell clone. In contrast, injection of the BDC 6.9 clone into pups from mothers producing BDC 2.5 TCIK clonotype-specific antibodies resulted in accelerated diabetes with an incidence similar to that in control pups from nonimmunized mothers. As described above, the islet-specific BDC 6.9 T cell clone is clonotypicaily distinct from BDC 2.5; therefore the protection against adoptively transferred disease afforded by matemal immunization appeared to be immunologically specific. The immunological specificity of the maternally transferred protection was further demonstrated by the failure of immunization against the D10 clonotype to provide protection ( Table 1 ). The BDC 2.5 TCIK clonotype specificity of the maternally transferred protection strongly suggests that it was mediated via the transfer of specific antibodies from the mother, either transplacentally or in milk, or by both routes. This interpretation was supported by the demonstration that 3-4-wk-old offspring of mothers successfully immunized with TCR-IgG1 protein contained titers of clonotype-specific antibodies between 1 / 100 and > 1 / 1000, as determined by indirect lmmunofluorescence.
Discussion
Infection of insect cells with recombinant baculovlrus has enabled the production of soluble BDC 2.5 TCR-IgG1 in the milligram amounts required for the immunization of mice. The recombinant protein was purified by CJJ-specific H57 mAb-lmmunoaflinity chromatography. SDS-PAGE of purified material under nonreducing conditions revealed a major species with an apparent molecular mass of 110 kD, which is within the range predicted from the molecular sizes of the BDC TCR ot-IgG1 and [3-IgG1 chains, and a larger species of"-,200 kD. Since reduction of purified protein yielded a band migrating in the size range expected for the separate chimeric chains (50-55 kiD), the larger non reduced species probably resulted from covalent aggregation due to mispaired disulfide bonds. Immunopreclpitation of approximately equal amounts of the purified protein with both the H57 mAb and the Cot-specific H28 mAb, as judged by SDS-PAGE, indicated that the H57-immunoaffinity purification yielded material that was mainly composed of ot/[3 heterodimers. The heterodimenc nature of the purified protein was also supported by equivalent reactivity with both mAb in a BIAcore experiment. Analysis of the conformation and functional activity of BDC 2.5 TC1K-IgG1 was not possible due to the lack ofa BDC 2.5 clonotype-specific mAb, and the unknown nature of the peptide which, when complexed with I-Ag 7 MHC class II molecule of the NOD mouse, forms the antigen for the BDC 2.5 T cell clone. We have, however, used a similar technique to produce and purify a soluble version of the D10 TCR in milligram amounts. In BIAcore experiments this recombinant protein was shown to bind the 3D3 mAb, which recognizes a conformational D10 clonotypic epltope, the V~-8 reactive SEC 2 superantigen, and the specific antigen complex of I-A k and conalbumm peptide (Khandekar et al., manuscript submitted for publication). Because immunization of NOD mice with the purified BDC 2.5 TCR-IgG1 stimulated the production of antibodies recognizing clonotypic epitopes of the BDC 2.5 cell surface TCR, it would appear that similarly to the soluble D10 TCR, structural features of the variable regions of the native TCR are possessed by the BDC 2.5 TCP,-IgG1 protein.
BDC 2.5 TCR-IgG1 immunization experiments provided evidence that when administered in a soluble form, a TCI< can be immunogenic in mice of the strain from which it was derived. Immunization of NOD mice with the NOD-derived BDC 2.5 TCR-IgG1 protein stimulated antibody responses against both constant-and variableregion epitopes of the TCR. The production of antibodies that both recognized clonotypic epitopes of the native cellsurface TCP, and inhibited antigen-specific activation of the BDC 2.5 T cell clone suggested that BDC 2.5 TCRIgG1 immunizations might block the induction of diabetes by the adoptive transfer of the BDC 2.5 clone in vivo. Using the maternal transfer of BDC 2.5 TCR.-specific antibodies we have indeed been able to demonstrate that soluble TCR immunization can bring about the clonal regulation of T cell function in vivo. There was a strong correlation between the production of TCP,. clonotypespecific antibodies in BDC 2.5 TCP,-IgG1 immunized NOD mothers and the inhibition of diabetes induction by the BDC 2.5 T cell clone in their offspring.
NOD mice that were immunized with BDC 2.5 TCP,.-IgG1 consistently mounted antibody responses against TCP, constant region epitopes. The NOD mouse anti-BDC 2.5 TCR-IgG1 antisera recognized antigens on baculovirusproduced soluble versions of the BDC 2.5 TCI<, the D10 TCP,, and the individual o~-and [3-chains of the D10 TCR. The antlsera did not react with these nonclonotypic antigens of TCR expressed in situ on the surface of T cell clones. It can be concluded that during immunization in vivo, the BDC 2.5 TCR-IgG1 protein presented TCP, constant region antigens to the immune system that are not normally exposed on the T cell surface. Furthermore, the reaction of the antisera with the constant region antigens could be detected by immunoblotting of BDC 2.5, BDC 6.9, D10, and B10 TCR immunoprecipitated from the respective T cell clones, indicating that some of the antigens are linear epitopes. It is possible that these epitopes were exposed and lmmunogenic in the recombinant soluble BDC 2.5 TCR-IgG1 preparations due to errors in folding, or partial denaturation of the protein. However, the ability of the antisera to immunoprecipitate TCP, from noniomc detergent extracts of different T cell clones suggests that native TCR constant region epitopes were recognized. The epitopes appear to be hidden in the TCR. when it is present in situ as an integral membrane protein of the T cell, probably due to their close proximity to either the cell-surface membrane, or components of the CD3 complex. Because they are normally unavailable for immune recognition, the constant region antigens presumably escape B cell tolerance during development of the immune system in vivo.
In addition to antibodies to the cryptic constant region epitopes, 56% of BDC 2.5 TC1K-IgG1 immunized NOD mice produced antibodies that strongly stained the BDC 2.5 cell surface by indirect immunofluorescence. The anti-sera did not stain either the BDC 6.9 T cell clone or NOD mouse splenic T cells, and whereas they blocked the antigen-specific activation of BDC 2.5 cells in vitro, they did not interfere with the activation of BDC 6.9 cells by the same antigen. Among the BDC 2.5 TCR epitopes recognized by the antisera, some at least appeared to be close enough to the V[3 segment to allow the antibodies to block, albeit to a relatively small extent, the binding of a V13-4 family-specific mAb to the BDC 2.5 cell-surface receptor. The antisera did not contain antibodies recognizing V13-4 family-specific epitopes, because they did not stain BDC 6.9 cells which also use the V13-4 gene segment. The data suggest that the antisera recognized BDC 2.5 clonotypic determinants.
The serologic specificities of the antibody response in NOD mice immunized with the syngeneic BDC 2.5 TCR-IgG1 do not seem to be unique because we have observed very similar responses in AKR mice immunized with soluble D10 TCP, (lesson, M.I., U. McKeever, S. Khandekar, J. Newcomb, J. Naylor, P. Gregory, P. Brauer, B. Bettencourt, J. Banerji, and B. Jones, manuscript in preparation). The effect of the IgG1 portion on the immunogenicity of the chimeric receptor has not been formally evaluated in the NOD mouse. Preliminary data in AKR mice indicated that soluble D10 dcTC1k produced in the baculovirus system without the IgG1 domams could also stimulate antibody responses. The responses were of similar potency and specificity to those mounted against the D10 TC1K-IgG1 protein, and therefore the Fc portion of the TCR-IgG1 protein does not appear to increase the immunogenicity of the TCIK appreciably.
The success of soluble TCR-IgG1 immunization in stimulating the production of antibodies recognizing native clonotypic epitopes of the BDC 2.5 TCR. led us to perform an experiment designed to investigate the concept that TC1K immunization in vivo can bring about the clonal regulation of autoimmune T cells. As explained in the introducnon to this article, we had to adopt a strategy of maternal immunization in order to provide TCR-specific serum antibodies in the young (2-3-wk-old) NOD mice used as recipients of the diabetogenic T cells. The data indicate that when BDC 2.5 TCR-IgG1 immunization successfully stimulated a BDC 2.5 clonotype-specific antibody response in the NOD mothers, then the litters were protected from the mduction of diabetes by the BDC 2.5 T cell clone. Protection appeared to be T cell clone specific because maternal immunization against the BDC 2.5 clonotype did not prevent the transfer of diabetes by the BDC 6.9 T cell clone. Imnmnological specificity was also supported by the failure of D10 TC1K-IgG1 immunizations that stimulated a D10 TC1K clonotype-specific antibody response in the NOD mothers to protect the offspring against diabetes induced by the BDC 2.5 T cell clone. As expected, BDC 2.5 TC1K-IgG1 immunizations that only stimulated a response to non-cell-surface TC1L constant region epitopes failed to afford protection in the litters.
The data demonstrate that using a relatively simple expression and purification strategy, it is possible to produce a soluble TCR-IgG1 protein in which the TCR. portion possesses clonotypic determinants that are immunogenic and cross-reactive with those found in the functionally active cell-surface form of the TCR.. The ability ofsyngeneic immunizations with BDC 2.5 TCR.-IgG1 to induce a humoral response that appeared to inhibit T cell-induced disease m a clone-specific fashion supports the concept that TCR. vaccinations that stimulate humoral immunity can potentially modulate the course of a T cell mediated autoimmune disease. The challenge now is to design TCR vaccination strategies that can alter the course of spontaneous autoimmune disease. Although in the outbred human population it seems unlikely that autoimmune diseases will be generally triggered by T cell clones that share a clonotypic epitope, multiple sclerosis may prove to be an exception. Oksenberg and colleagues (48) have found common amino acid sequence motifs in the VDJ region of T cells using the V~-5.2/3 gene segment in multiple sclerosis brain plaques. These VDJ sequences might represent immunogenic clonotypic epitopes that could be targeted by TCR vaccination. Recent experiments in an adoptive transfer model of mouse EAE with the encephalitogemc T cell clone L10C1 indicate that suppression of a single T cell clone can prevent disease (49) . L10Cl recognizes the MBP epitope p87-99, and the CDII.3 sequences in the TCR. ix-and [3-chains are homologous to those in rat clones specific for MBP p87-99 and human multiple sclerosis brain plaques. After injection of L10C1 cells into (PL/J × SJL/J)F1 mice, treatment of the mice with an altered peptide ligand prevented EAE. The heterogeneous expression of TCR genes observed in the inflammatory infiltrates of EAE induced by L10C1 in untreated mice was dramatically reduced by administration of the altered peptide ligand after the onset of paralysis. Our data demonstrating the efficacy of TCR. vaccination in the adoptive transfer model of mouse insnlin-dependent diabetes mellitus suggest that vaccination against the CDR3 epitope(s) shared by L10C1 and human brain plaque sequences could prevent disease in a similar fashion. Treatment with anti-TCR antibodies of appropriate specificity should also be effective, and in the human this would be a clinically acceptable approach.
While vaccination against TCI< clonotypes will probably not be applicable to all autoimmune diseases, vaccination against particular TCR. V-regions might be more feasible. Although the topic of TCP, V-gene usage in autoimmunity is controversial (50) , there are data to suggest that some human autoimmune diseases involve T cells that use a restricted repertoire of TCt< V-region segments, for example, TCR. V~-3, 6, 14, 15, and 17 in rheumatoid arthritis (51) (52) (53) (54) , and TCR. VI3-3 and 13.1 in the skin lesions of psoriasis (55) . The progression of such diseases might be ameliorated by soluble TCP,. immunizations that stimulate an antibody response against the family specific epitopes of the particular V[3 segments involved. Indeed, as mentioned in the introduction to this article, immunization against peptides derived from the TCR V[3-8.2 segment could sometimes prevent EAE in those strains of rat and mouse in which the encephalltogenic T cells use the V[3-8.2 gene predominantly. TCR peptide vaccination seems to prime T cells that regulate encephalitogenic T cell function via an ill-defined mechanism (7). In contrast, the mechanism of TCR.-specific antibody-mediated immunoregulation is comparatively straightforward, and we have now designed strategies where soluble TCR. immunizations can stimulate an antibody response that ohgoclonally modulates T cells usmg V~-genes belonging to a particular family. Mouse strains of the VI3" haplotype have a genomic deletion of the V~ 5, V[3 8, VI3 9, V~ 11, V~ 12, and V[3 13 gene loci (56) . Vaccination of these strains with a soluble TCR contaming one of the missing V~ segments should induce the formation of antibodies against its family-specific epitopes (57) . We are currently investigating the immunoregulatory activity of maternal immunization against a TCR V~-family in F1 offspring that inherit a functional complement of V~-gene segments from a father of a nondeleted strain.
